Why is GHRP-1 less commonly used than GHRP-2 or GHRP-6?

GHRP-1 has lower potency at the GHS-R1a receptor compared to its successors. GHRP-2 offers greater selectivity with less cortisol/prolactin elevation, while GHRP-6 provides stronger GH release magnitude. The development of more potent and selective analogs rendered GHRP-1 primarily of historical interest rather than practical research utility.

What is GHRP-1's significance in endocrinology?

GHRP-1 and its analogs directly led to the discovery of the GHS-R1a receptor and subsequently to the identification of ghrelin, the endogenous hunger hormone. This represents one of the few cases where a synthetic ligand led to the discovery of both a novel receptor and its natural ligand.

Does GHRP-1 stimulate appetite?

Yes, like all GHS-R1a agonists, GHRP-1 stimulates appetite through hypothalamic signaling. However, the magnitude of appetite stimulation has been less formally characterized compared to GHRP-2 and GHRP-6.

GHRP-1: Research Profile, Mechanism & Protocols | PepGuide

GHRP-1 is the first synthetic growth hormone releasing peptide discovered by Cyril Bowers, acting as a ghrelin receptor agonist with historical significance in the discovery of the GHS-R1a receptor and endogenous ghrelin.

Overview

GHRP-1 was among the first synthetic peptides demonstrated to stimulate growth hormone release independent of the GHRH pathway. Bowers and colleagues systematically modified enkephalin-derived peptides, discovering that certain hexapeptide configurations could potently release GH from pituitary somatotrophs through a then-unknown receptor. This work ultimately established an entirely new axis of GH regulation alongside GHRH and somatostatin. GHRP-1 is less commonly used in contemporary research compared to GHRP-2 and GHRP-6, which offer greater potency and better-characterized pharmacology.

Mechanism of Action

GHRP-1 binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed primarily on pituitary somatotrophs. Receptor activation triggers intracellular calcium mobilization via the phospholipase C/inositol trisphosphate pathway, leading to GH vesicle exocytosis. GHRP-1 acts through a mechanism distinct from GHRH, which signals through the GHRH receptor via cAMP/protein kinase A. This independent mechanism allows GHRPs to synergize with GHRH for amplified GH release. GHRP-1 also demonstrated cardioprotective activity in fetal heart cell cultures, reducing apoptosis through mechanisms shared with other GHRPs (Muccioli et al., 2000).

Reconstitution Calculator

Research

Growth Hormone Release

In comparative studies, GHRP-1 stimulates GH release from pituitary somatotrophs but with lower potency than GHRP-2 and GHRP-6. Bowers et al. demonstrated that structural modifications to the hexapeptide backbone could dramatically alter potency and selectivity, with GHRP-1 serving as the foundational scaffold from which more potent analogs were developed (Bowers et al., 1994). The peptide produces dose-dependent GH elevation with associated increases in cortisol and prolactin at higher doses.

Cardioprotection

Research in fetal heart cell cultures demonstrated that GHRP-1, along with GHRP-2 and GHRP-6, protects cardiomyocytes from apoptosis. This cardioprotective effect appears to be mediated through GHS-R1a signaling and is shared across the GHRP family, suggesting a conserved mechanism of cardiac cell survival independent of GH release (Muccioli et al., 2000).

Synergy with GHRH

Like other GHRPs, GHRP-1 demonstrates synergistic GH release when co-administered with GHRH or its analogs. Because GHRPs and GHRH activate distinct receptor pathways on somatotroph cells, the combined stimulus produces GH pulses 3-10 times greater than either agent alone. This synergy was first characterized using GHRP-1-class peptides and became a defining principle of growth hormone secretagogue pharmacology (Bowers, 1998).

Historical Discovery and GHS-R1a Identification

Cyril Bowers' systematic work with growth hormone releasing peptides throughout the 1980s and 1990s established the existence of a novel GH secretory pathway. GHRP-1 and its analogs demonstrated GH release that could not be explained by GHRH receptor activation, leading to the hypothesis and eventual cloning of the GHS-R1a receptor in 1996 by Howard et al. The subsequent identification of ghrelin as the endogenous GHS-R1a ligand in 1999 by Kojima et al. represented one of the most significant discoveries in endocrinology, connecting appetite, energy metabolism, and growth hormone regulation through a single receptor system (Bowers, 1998).

Safety Profile

GHRP-1 shares the general safety profile of growth hormone secretagogues. At standard research doses, it produces transient elevations in cortisol and prolactin that are dose-dependent and generally within physiological ranges. As with all GHS-R1a agonists, appetite stimulation and mild water retention may occur. GHRP-1 has been less extensively studied than GHRP-2 and GHRP-6, and comprehensive human safety data are limited. No serious adverse effects have been reported in published research at standard dosing.

Clinical Research Protocols

GHRP-1 has primarily been used in early investigational studies characterizing the GHS-R1a pathway rather than in formal clinical trials. Bowers and colleagues administered GHRP-1 intravenously at doses ranging from 0.1 to 1.0 mcg/kg in healthy volunteers, measuring serial GH, cortisol, and prolactin levels at 15-minute intervals for 60-90 minutes post-injection. These protocols established the dose-response characteristics and hormonal side-effect profile that guided development of subsequent GHRPs (Bowers et al., 1994). GHRP-1 was largely superseded by GHRP-2 for diagnostic applications due to the latter's greater potency and selectivity.

Synergies & Combinations

The primary documented synergy for GHRP-1 is with GHRH and its analogs. Co-administration produces synergistic rather than additive GH release, a property conserved across all GHRPs. In practice, GHRP-2 or ipamorelin have replaced GHRP-1 in combination protocols due to superior potency and selectivity. The GHRP + GHRH synergy principle first demonstrated with GHRP-1-class peptides remains the foundation of modern GH secretagogue combination research (Bowers, 1998).

Pharmacokinetic Profile

GHRP-1 — Pharmacokinetic Curve

Subcutaneous injection, Intravenous

Half-life: 23mT_max: 9mDuration shown: 1.9h

Quick Start

Route: Subcutaneous injection, Intravenous

Molecular Structure

2D Structure

Molecular Properties

Formula: C51H62N12O7
Weight: 955.1 Da
CAS: 142033-37-0
PubChem CID: 10350910
Exact Mass: 954.4864 Da
LogP: 2.8
TPSA: 314 Å²
H-Bond Donors: 11
H-Bond Acceptors: 10
Rotatable Bonds: 25
Complexity: 1750

Identifiers (SMILES, InChI)

InChI

InChI=1S/C51H62N12O7/c1-30(53)46(65)60-44(26-37-28-55-29-57-37)51(70)63-42(24-33-19-20-34-14-6-7-15-35(34)22-33)48(67)58-31(2)47(66)61-43(25-36-27-56-39-17-9-8-16-38(36)39)50(69)62-41(23-32-12-4-3-5-13-32)49(68)59-40(45(54)64)18-10-11-21-52/h3-9,12-17,19-20,22,27-31,40-44,56H,10-11,18,21,23-26,52-53H2,1-2H3,(H2,54,64)(H,55,57)(H,58,67)(H,59,68)(H,60,65)(H,61,66)(H,62,69)(H,63,70)/t30-,31-,40-,41+,42+,43-,44-/m0/s1

InChIKeyNWQWNCILOXTTHF-HLCSKTDOSA-N

Research Protocols

intravenous Injection

Bowers and colleagues administered GHRP-1 intravenously at doses ranging from 0.1 to 1.0 mcg/kg in healthy volunteers, measuring serial GH, cortisol, and prolactin levels at 15-minute intervals for 60-90 minutes post-injection.

Goal	Dose	Frequency	Duration
General Research Protocol	1.0 mcg	Per protocol	—(Route: Intravenous Injection)

subcutaneous Injection

Administered via subcutaneous injection.

Interactions

Peptide Interactions

✦

GHRHsynergistic

✦

Ipamorelinsynergistic

In practice, GHRP-2 or ipamorelin have replaced GHRP-1 in combination protocols due to superior potency and selectivity.

✓

GHRP-2compatible

GHRP-1 is less commonly used in contemporary research compared to GHRP-2 and GHRP-6, which offer greater potency and better-characterized pharmacology.

✓

GHRP-6compatible